

Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. *Nature*, 407(6801), 249-257.

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. *Cancer cell*, 8(4), 299-309.

Castillejos-Molina, R., Rodriguez-Covarrubias, F., Sotomayor, M., Gomez-Alvarado, M. O., Villalobos-Gollás, M., Gabilondo, F., & Feria-Bernal, G. (2011). Impact of metabolic syndrome on biochemical recurrence of prostate cancer after radical prostatectomy. *Urologia Internationalis*, 87(3), 270-275.

Chanan-Khan, A. A., & Cheson, B. D. (2008). Lenalidomide for the treatment of B-cell malignancies. *Journal of Clinical Oncology*, 26(9), 1544-1552.

Chang, J. W. C., Liu, H. P., Hsieh, M. H., Fang, Y. F., Hsieh, M. S., Hsieh, J. J., ... & Huang, S. F. (2008). Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients. *Lung Cancer*, 61(3), 328-339.

Chung, A. S., Lee, J., & Ferrara, N. (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. *Nature Reviews Cancer*, 10(7), 505-514.

Colorado, P. C., Torre, A., Kamphaus, G., Maeshima, Y., Hopfer, H., Takahashi, K., ... & Kalluri, R. (2000). Anti-angiogenic cues from vascular basement membrane collagen. *Cancer research*, 60(9), 2520-2526.

Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002). Matrix metalloproteinase inhibitors and cancer—trials and tribulations. *Science*, 295(5564), 2387-2392.